Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
K.S. Ginsburg, M.H. Liang, L. Newcomer, et al.
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis.
Ann Int Med, 117 (1992), pp. 997-1002
[2.]
O. Vaarala, M. Manttari, V. Manninen, et al.
Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.
Circulation, 91 (1995), pp. 23-27
[3.]
N.M. Shah, M.A. Khamashta, T. Atsumi, G.R.V. Hughes.
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients.
Lupus, 7 (1998), pp. 3-6
[4.]
M. Petri.
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.
Curr Rheumatol Rep, 5 (2003), pp. 370-373
[5.]
J. Girón-González, E. Del Río, C. Rodríguez, et al.
Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
J Rheumatol, 31 (2004), pp. 1560-1567
[6.]
M. Petri.
Thrombosis and systemic lupus erytheamtosus: the Hopkins lupus cohort perspective.
Scand J Rheumatol, 25 (1996), pp. 191-193
[7.]
D. Alarcón-Segovia, M.C. Boffa, W. Branch, et al.
Prophylaxis of the antiphospholipid syndrome: a consensus report.
Lupus, 12 (2003), pp. 499-503
[8.]
P.M. Ridker, N.R. Cook, I.-Min. Lee, et al.
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
N Engl J Med, 352 (2005), pp. 1293-1304
[9.]
M.A. Khamashta.
Management of thrombosis in the antiphospholipid syndrome.
Hughes syndrome. The antiphospholipid syndrome, pp. 391-396
[10.]
M.H. Rosove, P.M.C. Brewer.
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Ann Intern Med, 117 (1992), pp. 303-308
[11.]
M.A. Khamashta, M.J. Cuadrado, F. Mujic, et al.
The management of thrombosis in the antiphospholipid syndrome.
N Engl J Med, 332 (1995), pp. 993-997
[12.]
S. Schulman, E. Svenungsson, S. Granqvist, et al.
Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy.
Am J Med, 104 (1998), pp. 332-338
[13.]
C. Kearon, M. Gent, J. Hirsh, et al.
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
N Engl J Med, 340 (1999), pp. 901-907
[14.]
R.H.W.M. Derksen, P.G. De Groot, L. Kater, et al.
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.
Ann Rheum Dis, 52 (1993), pp. 689-692
[15.]
S. Krnic-Barrie, C.R. O’Connor, S.W. Looney, et al.
A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis.
Arch Intern Med, 157 (1997), pp. 2101-2108
[16.]
A. Rance, J. Emmerich, J.N. Fiessinger, et al.
Anticardiolipin antibodies and recurrent thromboembolism.
Thromb Haemost, 77 (1997), pp. 221-222
[17.]
H.I. Brunner, W.S. Chan, J.S. Ginsberg, B.M. Feldman.
Longterm anticoagulation is preferable for patients with antiphospholipid syndrome: result of a decision analysis.
J Rheumatol, 29 (2002), pp. 490-501
[18.]
M.A. Crowther, J.S. Ginsberg, M. Gent, et al.
A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies.
N Engl J Med, 349 (2003), pp. 1133-1138
[19.]
F.A. Al Sayegh, S. Ensworth, S. Huang, et al.
Hemorragic complications of long-term anticoagulant therapy in seven patients with systemic lupus erytheamtosus and antiphospholipid syndrome.
J Rheumatol, 24 (1997), pp. 1716-1718
[20.]
J. Hirsh, C. Kearon, J. Ginsberg.
Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia.
Arch Intern Med, 157 (1997), pp. 2174-2177
[21.]
Van der Meer FJ, Rosendal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 153:1557-62.
[22.]
M.J. Cuadrado.
Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome).
Curr Rheumatol Reports, 4 (2002), pp. 392-398
[23.]
R.G. Hart, O. Benavente, R. McBride, L.A. Pearce.
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
Ann Intern Med, 131 (1999), pp. 1164-1169
[24.]
G. Castellino, M.J. Cuadrado, T. Godfrey, et al.
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
Ann Rheum Dis, 60 (2001), pp. 527-530
[25.]
G. Ruiz-Irastorza, M.A. Khamashta, B.J. Hunt, et al.
Bleeding and recurrent thrombosis in definite antiphospholipid syndrome.
Arch Intern Med, 162 (2002), pp. 1164-1169
[26.]
R.H.W.M. Derksen, P.G. De Groot.
Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anti-coagulation?.
J Autoimmun, 15 (2000), pp. 255-259
[27.]
P.L. Meroni, M. Moia, R.H.W.M. Derksen, et al.
Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis.
Lupus, 12 (2003), pp. 504-507
[28.]
G.W. Albers, J.D. Easton, R.L. Sacco, P. Teal.
Antithrombotic and thrombolytic therapy for ischemic stroke.
Chest, 114 (1998), pp. 683-698
[29.]
G.W. Albers, J.G. Tijssen.
Antiplatelet therapy: new foundations for optimal treatment decisions.
Neurology, 53 (1999), pp. 25-31
[30.]
S.R. Levine, L. Salowich-Palm, K.L. Sawaya, et al.
IgG anticardiolipin antibody titers > 40GPL and the risk of subsequent thrombo-occlusive events and death: a prospective cohort study.
Stroke, 28 (1997), pp. 1660-1665
[31.]
S.R. Levine, R.L. Brey, B.C. Tilley, et al.
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.
JAMA, 291 (2004), pp. 576-584
[32.]
The Haemostasis and Thrombosis Task Force: BCSH guidelines on oral anticoagulation. Br J Haematol. 1998;101:374-87.
[33.]
R.F. Van Es, J.J. Jonker, F.W. Verheugt, et al.
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.
Lancet, 360 (2002), pp. 109-113
[34.]
M. Hurlen, M. Abdelnoor, P. Smith, et al.
Warfarin, aspirin, or both after myocardial infarction.
N Engl J Med, 347 (2002), pp. 969-974
[35.]
K. Lechner, I. Pabinger-Fasching.
Lupus anticoagulant and thrombosis.
Hemostasis, 15 (1985), pp. 254-262
[36.]
Italian Registry of Antiphospholipid Antibodies. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Hematologica. 1993;78:313-8.
[37.]
G. Finazzi, V. Brancaccio, M. Moia, et al.
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A fouryear prospective study from the Italian Registry.
Am J Med, 100 (1996), pp. 530-536
[38.]
P. Gordon, M.A. Khamashta, G.R.V. Hughes, B.J. Hunt.
Patterns of cerebrovascular disease in the Hughes/antiphospholipid syndrome (APS).
Arthritis Rheum, 43 (2000), pp. S309
[39.]
M.J. Cuadrado, M.A. Khamashta, D. Cruz, G.R.V. Hughes.
Migraine in Hughes syndrome.
Q J Med, 94 (2001), pp. 114-115
[40.]
M.J. Cuadrado, M.A. Khamashta, A. Ballesteros, et al.
Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis?.
Medicine (Baltimore), 79 (2000), pp. 57-68
[41.]
M. Lockshin, F. Tenedios, M. Petri, et al.
Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report.
Lupus, 12 (2003), pp. 518-523
[42.]
N. Espínola-Zavaleta, J. Vargas-Barrón, T. Colmenares-Galvis, et al.
Echocardiographic evaluation of patients with primary antiphospholipid syndrome.
Am Heart J, 137 (1999), pp. 973-978
[43.]
R. García-Torres, M.C. Amigo, A. De la Rosa, et al.
Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings.
Lupus, 5 (1996), pp. 56-61
[44.]
H. Amital, P. Langevitz, Y. Levy, et al.
Valvular deposition of antiphpspholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease.
Clin Exp Rheumatol, 17 (1999), pp. 99-102
[45.]
A. Afek, Y. Shoenfeld, R. Manor, et al.
Increased endothelial cell expression of alpha 3 beta 1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome.
Lupus, 8 (1999), pp. 502-507
[46.]
N. Espínola-Zavaleta, R.M. Montes, M.E. Soto, et al.
Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow-up study.
J Rheumatol, 31 (2004), pp. 2402-2407
[47.]
R.A.S. Roubey.
New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials and tribulations.
Arthritis Rheum, 48 (2003), pp. 3004-3008
[48.]
P.L. Meroni, E. Raschi, C. Testoni, et al.
Statins prevent endothelial cell activation induced by antiphospholipid (anti-B2-glycoprotein 1) antibodies: effect on the proadhesive and proinflammatory phenotype.
Arthritis Rheum, 44 (2001), pp. 2870-2878
[49.]
D.E. Ferrara, X. Liu, R.G. Espinola, et al.
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.
Arthritis Rheum, 48 (2003), pp. 3272-3279
[50.]
R. Johnson, J. Charnley.
Hydroxycloroquine in prophylaxis of pulmonary embolism following hip arthroplasty.
Clin Orthop, 144 (1979), pp. 174-177
[51.]
R.G. Espinola, S.S. Pierangeli, A.E. Gharavi, E.N. Harris.
Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.
Thromb Haemost, 87 (2002), pp. 518-522
[52.]
M.H. Edwards, S. Pierangeli, X.W. Liu, et al.
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice.
Circulation, 96 (1997), pp. 4380-4384
[53.]
F.D. Goldman, A.L. Gilman, C. Hollenback, et al.
Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.
Blood, 95 (2000), pp. 3460-3466
[54.]
P.M. Dobado-Berrios, C. López-Pedrera, F. Velasco, M.J. Cuadrado.
The role of tissue factor in antiphospholipid syndrome.
Arthritis Rheum, 44 (2001), pp. 2467-2476
[55.]
K. Cockerill, M.D. Linnik, D.S. Jones, et al.
A novel therapeutic approach for treating antiphospholipid syndrome based on tolerizing anti-B2-GP1 B cells.
Arthritis Rheum, 46 (2002), pp. 230
[56.]
M. Blank, I. Krause, Y. Shoenfeld.
The contribution of experimental models to our understanding of etiology, pathogenesis and novel therapies in the antiphospholipid syndrome.
Hughes syndrome: antiphospholipid syndrome, pp. 379-388
Copyright © 2005. Elsevier España S.L. Barcelona
